TGTheodore G. Ganiats

Theodore G. Ganiats

*This is an algorithmically generated author record based on publicly available information.

Theodore G. Ganiats has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential

    by Steffie K Naber, Suman Kundu, Karen M Kuntz, W David Dotson, Marc S Williams, Ann G Zauber, Ned Calonge, Doris T Zallen, Theodore G Ganiats, Elizabeth M Webber, et al.

    Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-based screening may be more efficient. We investigated whether CRC screening based on polygenic risk is a cost-effective alternative to current uniform screening, and if not, under what conditions it would be.Methods: The MISCAN-Colon model was used to simulate a hypothetical cohort of US 40-year-olds. Uniform screening was modeled as colonoscopy screening at ages 50, 60, and 70 years. For risk-stratified screening, individuals underwent polygenic testing with current and potential future discriminatory performance (area under the receiver-operating curve [AUC] of 0.60 and 0.65–0.80, respectively). Polygenic testing results were used to create risk groups, for which colonoscopy screening was optimized by varying the start age (40–60 years), end age (70–85 years), and interval (1–20 years).Results: With current discriminatory performance, optimal screening ranged from once-only colonoscopy at age 60 years for the lowest-risk group to six colonoscopies at ages 40–80 years for the highest-risk group. While maintaining the same health benefits, risk-stratified screening increased costs by $59 per person. Risk-stratified screening could become cost-effective if the AUC value would increase beyond 0.65, the price per polygenic test would drop to less than $141, or risk-stratified screening would lead to a 5% increase in screening participation.Conclusions: Currently, CRC screening based on polygenic risk is unlikely to be cost-effective compared with uniform screening. This is expected to change with a greater than 0.05 increase in AUC value, a greater than 30% reduction in polygenic testing costs, or a greater than 5% increase in adherence with screening.


  • Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer

    by Steffie K. Naber, Karen M. Kuntz, Nora B. Henrikson, Marc S. Williams, Ned Calonge, Katrina A.B. Goddard, Doris T. Zallen, Theodore G. Ganiats, Elizabeth M. Webber, A. Cecile J.W. Janssens, et al.


  • Self-reported calcium use in a cohort of postmenopausal women receiving osteoporosis therapy: results from POSSIBLE US™

    by E. Barrett-Connor, S. W. Wade, R. W. Downs, T. Ganiats, M. Hochberg, R. R. Recker, B. S. Stolshek

    Calcium use was common and remained high among women on osteoporosis therapy. Use of calcium-supplemented pharmacologic therapy increased from 65.1 to 76.0 % in these women (mean follow-up, 27.5 months). Over 12 months, calcium discontinuation was fairly similar among women using calcium only (23.7 %) and women supplementing pharmacologic therapy with calcium (22.5 %). Calcium has an important role in bone health. This study describes calcium use and persistence in a postmenopausal osteoporosis treatment cohort. Subject-reported calcium use was analyzed for 3,722 participants of the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE USTM) who used calcium either as their sole osteoporosis treatment (calcium only) or to supplement pharmacologic osteoporosis therapy (supplementers). Descriptive analyses were conducted. Kaplan-Meier methods were used to estimate the probability of discontinuing calcium therapy, and logistic regression was used to assess associations (age-adjusted odds ratios) between healthy behaviors and calcium use. At entry, there were 711 calcium-only subjects and 1,960 of 3,011 subjects on pharmacologic osteoporosis therapy also supplementing with calcium (supplementers). The percentage of supplementers increased from 65.1 to 76.0 % during follow-up (mean, 27.5 months). During the first 12 months on study, the probability of calcium discontinuation was 23.7 % (95 % confidence interval [CI], 20.7 − 27.0) among calcium-only subjects and 22.5 % (95 % CI, 20.7–24.5) among supplementers. Supplementers who discontinued pharmacologic therapy were more likely to discontinue calcium than supplementers who continued pharmacologic therapy (34.9 versus 14.8 %). Overall 54.2 % of calcium-only subjects who discontinued calcium and 42.3 % of supplementers who discontinued calcium resumed calcium use during follow-up. Regular exercise was positively correlated with calcium use at study entry. Calcium supplementation in pharmacologically treated subjects increased over time. Persistence with calcium was high. Discontinuation of pharmacologic osteoporosis therapy was associated with an increased likelihood of discontinuing calcium use.


  • Open Access

    Family history and the natural history of colorectal cancer: systematic review

    by Nora B. Henrikson, Elizabeth M. Webber, Katrina A. Goddard, Aaron Scrol, Margaret Piper, Marc S. Williams, Doris T. Zallen, Ned Calonge, Theodore G. Ganiats, A. Cecile J.W. Janssens, et al.


  • Medicaid Coverage of Tobacco-Dependence Treatment for Pregnant Women

    by Sara B. McMenamin, Helen Ann Halpin, Theodore G. Ganiats


  • The Debate About Over-the-Counter Emergency Contraceptive Pills

    by Chih-Wen Shi, Theodore G. Ganiats

    Many prescription drugs have been converted to over-the-counter (OTC) status in recent years. Another drug that has been proposed for OTC status is a levonorgestrel-only emergency contraceptive pill. The debate surrounding OTC access to emergency contraceptive pills echoes issues encountered in previous reclassification processes and raises new challenges. This article discusses the emergency contraceptive pill, the evolution of its access options, and the context and implications of changing its status from a prescription to an OTC medication.


  • Family Medicine: Principles and Practice

    by Theodore G. Ganiats

    To create a specialty textbook the editor must somehow come up with a single work that summarizes the essence of the specialty. In any specialty this is difficult, but in many ways the specialty of family practice, because of its breadth, makes this effort all the more challenging. In its fourth edition, Taylor's Family Medicine: Principles and Practice clearly rises to the challenge. A textbook like this should be judged on its readability, including organization, comprehensiveness, and timeliness. A key element would be the quality of the authors and how well the book comes together as a unit despite having multiple authors. Dr Taylor has assembled a veritable Who's Who in family medicine with about 200 authors. However, the book maintains the feel of the work of a smaller group and is exquisite in its organization and presentation. The text is divided into three parts. The first discusses the specialty